Detail akcie Nektar Therap online

Business Summary: Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Nektar Therapeutics revenues remained flat at $21.6M. Net loss decreased 73% to $36.8M. Revenues reflect Product sales increase of 28% to $6M, License, collaboration and other increase from $15K to $97K, also reflect Non-cash royalty revenue related to the decrease of 8% to $15.5M. Lower net loss reflects Impairment of goodwill decrease from $76.5M (expense) to $0K.